Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients 16 Years With Centronuclear Myopathies

  • STATUS
    Recruiting
  • End date
    Apr 19, 2022
  • participants needed
    18
  • sponsor
    Dynacure
Updated on 19 February 2021

Summary

There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, PK and PD/preliminary efficacy of a new medicine called DYN101 in patients 16 years of age with CNM caused by mutations in DNM2 or MTM1.

The trial will consist of a consent, a screening period, a run-in period (if applicable), a Single dose treatment part (SAD) with 4 weeks of follow-up after the drug administration and a washout period of at least 12 weeks (followed by follow-up phone calls), a Multiple dose treatment part (MAD) of 12 weeks of weekly dosing, and a Multiple dose extension part of 12 weeks. All subjects will participate in the SAD, MAD, and MAD extension parts, unless they withdraw. During this time, multiple test will be performed in order to better understand how the drug is distributed and then later removed from the body and whether there any signs of an effect.

As this trial is investigational, there is no defined, expected benefit for subjects who participate in this trial except a better knowledge of their disease.

Description

There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, PK and PD/preliminary efficacy of DYN101 in patients 16 years of age with CNM caused by mutations in DNM2 or MTM1.

DYN101 is a synthetically manufactured constrained ethyl gapmer ASO directed against DNM2 pre-mRNA. DYN101 will be provided as a sterile concentrated solution for reconstitution into an infusion solution for intravenous (IV) administration, and will be diluted into a 0.9% sodium chloride solution before administration.

The trial will consist of a pre-screening consent, a screening period, a run-in period (if applicable), a SAD part with 4 weeks of follow-up after IMP administration and a washout period of at least 12 weeks (followed by follow-up phone calls until the MAD part starts), a MAD part of 12 weeks, and a MAD extension part of 12 weeks. All subjects will participate in the SAD, MAD, and MAD extension parts, unless they withdraw. End-of-treatment assessments will be performed after 24 weeks of MAD treatment have been completed, i.e. at the Week 25 visit. Subjects will be followed up on adverse events (AEs) and concomitant medications 3 months after the last IMP administration.

The primary analysis will be performed when all subjects in all cohorts have completed 12 weeks of MAD treatment or discontinued earlier. The final analysis will be performed when all subjects have completed 24 weeks of MAD treatment (12 weeks in the MAD part + 12 weeks in the MAD extension part; Week 25 visit) or discontinued earlier.

As this trial is investigational, there is no defined, expected benefit for subjects who participate in this trial except a better knowledge of their pathology, and the knowledge that they contribute to RNA-targeted therapy for CNM patients carrying MTM1 and DNM2 mutations.

Details
Condition Centronuclear myopathy
Treatment DYN101
Clinical Study IdentifierNCT04033159
SponsorDynacure
Last Modified on19 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female aged 16 years on the date of signing the main Informed Consent Form (ICF)
Have a documented mutation in DNM2 or MTM1
Meet the following criteria at screening
Platelet count > 150,000/L
Normal kidney function, as supported by values of blood urea nitrogen (BUN), creatinine, cystatin C, and estimated Glomerular Filtration Rate (eGFR); all abnormal results of these tests should have a medically plausible reason and should be discussed with the medical monitor before the subject may be screened and/or dosed for the study
Normal liver function, as supported by values of Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyltransferase (GGT), and bilirubin not higher than 1.5 times the upper limit of normal. There should be a medically plausible reason for the elevation of these parameters outside of the normal range, and a discussion with the medical monitor should occur in this situation before the subject may be screened and/or dosed for the study
Note: Retesting of subjects should always be discussed with the sponsor and/or
medical monitor. Retesting of laboratory values that lead to exclusion will be
allowed once using an unscheduled visit during the screening period to assess
eligibility. This visit should be at least 2 weeks later than the original
screening visit
\. Have a symptomatic CNM in the opinion of the investigator, at least mild
to moderately affected, i.e. showing clinical symptoms in at least 2 of the
domains that will be investigated in this trial (respiratory, muscle strength
and function, dysphagia), and be ambulatory, i.e. being able to walk 10 steps
if needed with support/assisted. If a subject is non-ambulatory but highly
functioning in the view of the investigator, he/she may be included following
discussion with the sponsor
\. Have an understanding, ability, and willingness to fully comply with visit
frequency, trial procedures and restrictions, including contraceptive
requirements
\. Able to provide written, signed and dated informed consent/assent to
participate in the trial. Parental consent (one or both parents) and an assent
for subjects < 18 years may be required per local legislation

Exclusion Criteria

Have clinical, or ultrasound evidence of liver disease. Note: Liver ultrasound at screening is mandatory for MTM1 subjects
Presence of significant co-morbidities or conditions other than CNM or clinically significant (CS) findings during screening of medical history, physical examination, laboratory testing, vital signs or ECG recording for which, in the opinion of the investigator and the medical monitor, participation would not be in the best interest of the subject (e.g. compromise the safety or well-being) or that could prevent, limit, or confound the protocol-specified assessments (e.g. taking a muscle biopsy)
For female subjects of child-bearing potential: pregnant or breastfeeding, or planning to become pregnant during the trial
Current or past abuse of alcohol or recreational/narcotic drugs (with the exception of caffeine and nicotine), which in the investigator's opinion would compromise the subject's safety and/or compliance with the trial procedures
Currently enrolled in any interventional trial or scheduled to participate in such a trial whilst participating in this trial. Subjects are allowed to participate in registry studies
Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the trial, or any condition that presents undue risk from the IMP or procedures
Intake of any disallowed therapies as noted in Section 5.5 within 12 weeks before the planned first IMP administration
Known or suspected intolerance or hypersensitivity to IMP ingredients or closely-related compounds, or history of a significant allergic reaction to IMP ingredients as determined by the investigator, such as anaphylaxis requiring hospitalization
Legally incapacitated or have limited legal capacity. Lack of mental capacity to fully understand the protocol requirements and complete all study required procedures
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note